GlycoFi in Merck alliance

Lebanon-based GlycoFi has established a strategic alliance and multi-year research collaboration with Merck & Co. Inc., the pharmaceutical giant, that will focus on he use of GlycoFi’s yeast-based glycoprotein optimization platform to develop biologic and vaccine drug candidates.

The companies said GlycoFi and Merck scientists will work together to deploy GlycoFi’s technology to produce and optimize various pharmaceutical properties of a broad range of Merck’s biologic drug candidates, including vaccines, antibodies, and other therapeutic proteins.

Under the terms of the agreement, Merck will make an up-front cash payment and an equity investment in GlycoFi and fund GlycoFi’s research efforts.

GlycoFi is a venture-backed, biotechnology company whose investors include Polaris Venture Partners, SV Life Sciences, Boston Millennia Partners and Fletcher Spaght Ventures. – NHBR STAFF